SCHEMBL2882847

SCHEMBL2882847

CCOC(=O)CCc1cccnc1Cl

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 3/20 0.57
CYP4A11 Q02928 3/20 0.57
ALDH1A1 P00352 3/20 0.48
GAA P10253 1/20 0.48
LMNA P02545 3/20 0.47
CYP2C19 P33261 1/20 0.45
MAPT P10636 2/20 0.45
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
KDM4E B2RXH2 2/20 0.42
HSD17B10 Q99714 2/20 0.42
TP53 P04637 1/20 0.42
HPGD P15428 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
DGAT2 Q96PD7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8664219 0.85 CYP4F2 (0.60) CYP4F2CYP4A11ALDH1A1GAALMNA
SCHEMBL3587106 0.85 MAPT (0.46) CYP4F2CYP4A11ALDH1A1LMNACYP2C19
SCHEMBL30178346 0.85 CYP4F2 (0.60) CYP4F2CYP4A11ALDH1A1GAALMNA
SCHEMBL28419091 0.84 CYP4F2 (0.59) CYP4F2CYP4A11ALDH1A1GAALMNA
SCHEMBL27783318 0.83 LMNA (0.43) CYP4F2CYP4A11ALDH1A1LMNACYP2C19
SCHEMBL30949990 0.82 CYP4F2 (0.57) CYP4F2CYP4A11ALDH1A1GAALMNA
SCHEMBL1511082 0.82 CYP4F2 (0.57) CYP4F2CYP4A11ALDH1A1GAALMNA
SCHEMBL6349935 0.82 CYP4F2 (0.57) CYP4F2CYP4A11ALDH1A1GAALMNA
Hydrochloric Acid SCHEMBL6779477 0.81 CYP4F2 (0.56) CYP4F2CYP4A11ALDH1A1GAALMNA
SCHEMBL31299043 0.81 CYP4F2 (0.49) CYP4F2CYP4A11ALDH1A1GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3702354-B1 COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF HAIHE BIOPHARMA CO LTD (CN) 2024-05-22 EP disclosed
US-11465984-B2 Compound having ERK kinase inhibitory activity and use thereof SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) 2022-10-11 US disclosed
EP-3702354-A1 COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF Shanghai Haihe Pharmaceutical Co., Ltd. (CN) 2020-09-02 EP disclosed
EP-3702354-A1 COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF Shanghai Haihe Pharmaceutical Co., Ltd. (CN) 2020-09-02 EP disclosed
US-20200247781-A1 COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF HAIHE BIOPHARMA CO., LTD. (CN) 2020-08-06 US disclosed
US-20200247781-A1 COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF HAIHE BIOPHARMA CO., LTD. (CN) 2020-08-06 US disclosed
WO-2019062949-A1 COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF 上海海和药物研究开发有限公司 2019-04-04 WO disclosed
CN-1930145-B Cycloalkanopyridine derivative MSD CO LTD 2011-06-15 CN disclosed
US-7855294-B2 Cycloalkanopyridine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-12-21 US disclosed
US-7855294-B2 Cycloalkanopyridine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-12-21 US disclosed
US-7855294-B2 Cycloalkanopyridine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-12-21 US disclosed
US-20070191419-A1 Cycloalkanopyridine derivative MSD K.K. (JP) 2007-08-16 US disclosed
US-20070191419-A1 Cycloalkanopyridine derivative MSD K.K. (JP) 2007-08-16 US disclosed
US-20070191419-A1 Cycloalkanopyridine derivative MSD K.K. (JP) 2007-08-16 US disclosed
CN-1930145-A Cycloalkanopyridine derivative BANYU PHARMA CO LTD (JP) 2007-03-14 CN disclosed
EP-1726590-A1 CYCLOALKANOPYRIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11465984-B2 Compound having ERK kinase inhibitory activity and use thereof MAPK1, MAPK4, MAPK7 CYP4F2 1132/4885CYP4A11 577/4885ALDH1A1 1025/4885
US-20200247781-A1 COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF MAPK1, MAPK4, MAPK7 CYP4F2 1132/4885CYP4A11 577/4885ALDH1A1 1025/4885
US-20070191419-A1 Cycloalkanopyridine derivative OPRL1, OPRK1, AVPR2 CYP4F2 4305/4885CYP4A11 3025/4885ALDH1A1 2000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.